Effects of menopausal hormone therapy on cardiovascular diseases and type 2 diabetes in middle-aged postmenopausal women: analysis of the Korea National Health Insurance Service Database
- 주제(키워드) Retrospective cohort study , Cardiovascular diseases , Menopausal hormone therapy , Postmenopausal women , Type 2 diabetes
- 주제(기타) Obstetrics & Gynecology
- 설명문(일반) [Kim, Ji-Eun; Park, JooYong; Choi, Ji-Yeob] Seoul Natl Univ, Dept Biomed Sci, Grad Sch, 103 Daehak Ro, Seoul 03080, South Korea; [Kim, Ji-Eun; Choi, Jaesung; Park, JooYong; Choi, Ji-Yeob] Seoul Natl Univ, Coll Med, BK21plus Biomed Sci Project, Seoul, South Korea; [Choi, Jaesung; Choi, Ji-Yeob] Seoul Natl Univ, Inst Hlth Policy & Management, Med Res Ctr, Seoul, South Korea; [Shin, Aesun] Seoul Natl Univ, Dept Prevent Med, Coll Med, Seoul, South Korea; [Shin, Aesun; Choi, Ji-Yeob] Seoul Natl Univ, Canc Res Inst, Seoul, South Korea; [Choi, Nam-Kyong] Ewha Womans Univ, Dept Hlth Convergence, Seoul, South Korea
- 등재 SCIE, SCOPUS
- 발행기관 LIPPINCOTT WILLIAMS & WILKINS
- 발행년도 2021
- URI http://www.dcollection.net/handler/ewha/000000190542
- 본문언어 영어
- Published As https://doi.org/10.1097/GME.0000000000001848
- PubMed https://pubmed.ncbi.nlm.nih.gov/34520413
초록/요약
Objective: Although menopausal hormone therapy (MHT) is the most effective treatment for menopausal symptoms, menopausal women hesitate to start MHT due to concerns about adverse events. Recently, however, it has been recommended to use it for appropriate patients who have been evaluated for baseline diseases, age, and timing of initiation. We aimed to investigate the association of MHT with cardiovascular diseases (CVDs) and type 2 diabetes among middle-aged postmenopausal women in Korea. Methods: Data were collected from the National Health Insurance Service database in Korea from 2002 to 2016. A total of 58,060 postmenopausal women (including 8,013 [13.8%] MHT users and 50,047 [86.2%] nonusers) were included. The time-dependent Cox regression model with a 1-year latency period was used to evaluate the hazard ratio (HR) and 95% confidence interval (CI) of the associations of MHT with CVDs and type 2 diabetes outcomes. Subgroup analyses by regimen type and cumulative duration were conducted. Results: In the multivariate-adjusted model, MHT was not significantly associated with CVDs (HR = 1.085, 95% CI: 0.899-1.310) or type 2 diabetes (HR = 1.104, 95% CI: 0.998-1.221). Differential effects were not observed by regimen type, cumulative duration, and years since menopause subgroups. Sensitivity analyses also did not show adverse events by MHT on CVDs and type 2 diabetes. Conclusions: Although protective effects of MHT against CVDs or type 2 diabetes were not observed among postmenopausal women who had screened underlying diseases, our results may contribute to reducing the current concerns about the use of MHT for middle-aged postmenopausal women in Korea.
more